Evoke Pharma Inc Form 4 October 02, 2013

### FORM 4

#### UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

Check this box

if no longer subject to Section 16. Form 4 or Form 5

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF **SECURITIES** obligations

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

(Print or Type Responses)

1(b).

(Last)

may continue.

See Instruction

1. Name and Address of Reporting Person \* WIDDER KENNETH J

(Middle)

2. Issuer Name and Ticker or Trading Symbol

Evoke Pharma Inc [EVOK]

3. Date of Earliest Transaction (Month/Day/Year) 09/30/2013

5. Relationship of Reporting Person(s) to

Issuer

below)

\_X\_\_ Director

(Check all applicable)

X\_\_ 10% Owner

\_ Other (specify

**OMB APPROVAL** 

3235-0287

January 31,

2005

0.5

**OMB** 

Number:

Expires:

response...

Estimated average

burden hours per

C/O EVOKE PHARMA, INC., 12555 HIGH BLUFF DRIVE, **SUITE 385** 

(First)

(Street) 4. If Amendment, Date Original Filed(Month/Day/Year)

6. Individual or Joint/Group Filing(Check Applicable Line)

Officer (give title

\_X\_ Form filed by One Reporting Person Form filed by More than One Reporting

SAN DIEGO, CA 92130

(City)	(State)	(Zip) Tab	le I - Non-	-Derivative Se	curitie	es Acqu	ired, Disposed o	f, or Beneficia	ally Owned
1.Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transactic Code (Instr. 8)	4. Securities of Disposed of (Instr. 3, 4 an	of (D)		5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	09/30/2013		C	1,054,262	A	<u>(1)</u>	1,054,262	I	Directly owned by LVP III (2)
Common Stock	09/30/2013		С	52,711	A	(1)	52,711	I	Directly owned by Associates
Common Stock	09/30/2013		C	26,356	A	(1)	26,356	I	Directly owned by Partners (2)

Common Stock 5,250 I Directly owned by LVPMC  $\stackrel{(2)}{\sim}$ 

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

SEC 1474 (9-02)

# Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)	5. Number of stiorDerivative Securities 3) Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Underlying Securities (Instr. 3 and 4)	
				Code V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Series A Preferred Stock (1)	(1)	09/30/2013		С		5,271,317	(3)	<u>(4)</u>	Common Stock	1,054,26
Series A Preferred Stock (1)	(1)	09/30/2013		C		263,556	(3)	<u>(4)</u>	Common Stock	52,711
Series A Preferred Stock (1)	(1)	09/30/2013		C		131,784	(3)	<u>(4)</u>	Common Stock	26,356

## **Reporting Owners**

Reporting Owner Name / Address	Relationships					
	Director	10% Owner	Officer	Other		
WIDDER KENNETH J						
C/O EVOKE PHARMA, INC.	X	X				
12555 HIGH BLUFF DRIVE, SUITE 385	Λ	Λ				
SAN DIEGO, CA 92130						

## **Signatures**

/s/ Matthew J. D'Onofrio, Attorney-in-fact for Kenneth J. Widder 10/02/2013

\*\*Signature of Reporting Person Date

Reporting Owners 2

#### **Explanation of Responses:**

- \* If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- The outstanding shares of Series A Preferred Stock automatically converted on a five-to-one basis into shares of Common Stock rounded (1) down to the next whole number for no additional consideration immediately prior to the consummation of the Issuer's initial public
  - The reported securities are owned directly by each of LVPMC, LLC ("LVPMC"), LVP Life Science Ventures III, L.P. ("LVP III"), LVP III Associates, L.P. ("Associates") and LVP III Partners, L.P. ("Partners"). LVP GP III, LLC ("GP III") is the general partner of LVP III,
- Associates and Partners. The reporting person, a member of GP III, shares voting and investment power with respect to these shares but disclaims beneficial ownership of these shares, except to the extent of his pecuniary interest therein.
- (3) The securities are immediately convertible.
- (4) The securities have no expiration date.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.